BCL2 and cancer: Studies have confirmed the feasibility of using the regulatory miR-15/16 of Bcl-2-associated X protein (BAX)/Bcl-2 homologous antagonist killer (BAK)-dependent pathway, the classical pathway of Bcl-2, to fight cancer (41).